Related Experiment Video
Updated: Jun 25, 2025
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a
Clara Caenepeel1, Sara Deleu2, Jorge Francisco Vazquez Castellanos3
1Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium; University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium.
Rigorous donor selection and fecal microbiota transplantation (FMT) did not improve remission rates in ulcerative colitis (UC) patients. Further research needs to optimize FMT protocols for better clinical outcomes in UC treatment.
Area of Science:
- Gastroenterology
- Microbiome Research
- Clinical Trials
Background:
- Ulcerative colitis (UC) treatment remains challenging, necessitating novel therapeutic approaches.
- Fecal microbiota transplantation (FMT) shows promise for inducing remission in UC.
- Optimizing FMT protocols, including donor selection and administration, is crucial for efficacy.
Purpose of the Study:
- To evaluate the efficacy of rigorously selected allogeneic versus autologous fecal microbiota transplantation (FMT) in inducing steroid-free remission in moderate to severe ulcerative colitis (UC).
- To assess the impact of donor preselection, anaerobic processing, and repeated FMT administration on treatment outcomes.
Main Methods:
- A multi-center, double-blind, sham-controlled, randomized trial (RESTORE-UC) involving 72 patients with moderate to severe UC.
- Patients received 4 anaerobic-prepared allogeneic or autologous donor FMTs.
- Primary endpoint: steroid-free clinical remission at week 8. Futility analysis at 66% enrollment.
Main Results:
- The trial was stopped early due to futility, with no significant difference in steroid-free remission between allogeneic and autologous FMT groups (3% vs. 5%).
- Microbiome analysis indicated more enterotype transitions with allogeneic FMT, particularly when the donor enterotype differed from the patient's baseline.
- Baseline factors associated with primary response included lower total Mayo scores, lower bacterial cell counts, and higher Bacteroides 2 prevalence.
Conclusions:
- The RESTORE-UC trial failed to demonstrate that rigorously selected allogeneic FMT improves remission rates in UC at week 8.
- Future research should explore enhanced patient selection, optimized FMT preparation (frequency, density, viability), and potentially different control groups.
